CL2020000056A1 - Nuevos derivados de xantina sustituidos. - Google Patents
Nuevos derivados de xantina sustituidos.Info
- Publication number
- CL2020000056A1 CL2020000056A1 CL2020000056A CL2020000056A CL2020000056A1 CL 2020000056 A1 CL2020000056 A1 CL 2020000056A1 CL 2020000056 A CL2020000056 A CL 2020000056A CL 2020000056 A CL2020000056 A CL 2020000056A CL 2020000056 A1 CL2020000056 A1 CL 2020000056A1
- Authority
- CL
- Chile
- Prior art keywords
- xanthine derivatives
- substituted xanthine
- new substituted
- derivatives
- trpc5
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
- 108090000862 Ion Channels Proteins 0.000 abstract 1
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 102000003621 TRPC5 Human genes 0.000 abstract 1
- 101150042815 TRPC5 gene Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180721 | 2017-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000056A1 true CL2020000056A1 (es) | 2020-06-12 |
Family
ID=59325162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000056A CL2020000056A1 (es) | 2017-07-11 | 2020-01-08 | Nuevos derivados de xantina sustituidos. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US10329292B2 (https=) |
| EP (1) | EP3652176B1 (https=) |
| JP (1) | JP7114702B2 (https=) |
| KR (1) | KR102714554B1 (https=) |
| CN (1) | CN110997675B (https=) |
| AR (1) | AR112448A1 (https=) |
| AU (1) | AU2018299824B2 (https=) |
| CA (1) | CA3066922A1 (https=) |
| CL (1) | CL2020000056A1 (https=) |
| CO (1) | CO2019015102A2 (https=) |
| CY (1) | CY1125014T1 (https=) |
| DK (1) | DK3652176T3 (https=) |
| EA (1) | EA039526B1 (https=) |
| ES (1) | ES2903268T3 (https=) |
| HR (1) | HRP20220029T1 (https=) |
| HU (1) | HUE057600T2 (https=) |
| IL (1) | IL271799B (https=) |
| LT (1) | LT3652176T (https=) |
| MX (1) | MX394089B (https=) |
| MY (1) | MY200797A (https=) |
| PE (1) | PE20200861A1 (https=) |
| PH (1) | PH12020500079A1 (https=) |
| PL (1) | PL3652176T3 (https=) |
| PT (1) | PT3652176T (https=) |
| RS (1) | RS62826B1 (https=) |
| SA (1) | SA519410851B1 (https=) |
| SG (1) | SG11201912168TA (https=) |
| SI (1) | SI3652176T1 (https=) |
| SM (1) | SMT202200013T1 (https=) |
| TW (1) | TWI801398B (https=) |
| UA (1) | UA124793C2 (https=) |
| WO (1) | WO2019011802A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093084A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| US12291532B2 (en) | 2018-12-12 | 2025-05-06 | Boehringer Ingelheim International Gmbh | Substituted xanthines as modulators of TRPC5 activity |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
| JP2022551580A (ja) * | 2019-10-04 | 2022-12-12 | ゴールドフィンチ バイオ，インク． | 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| WO2024164818A1 (zh) | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1368349B1 (de) * | 2001-02-24 | 2007-02-14 | Boehringer Ingelheim Pharma GmbH & Co.KG | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| CN107082782B (zh) * | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| JP6559228B2 (ja) | 2014-09-17 | 2019-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 |
-
2018
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 PE PE2019002691A patent/PE20200861A1/es unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 KR KR1020207000260A patent/KR102714554B1/ko active Active
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en not_active Ceased
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 SM SM20220013T patent/SMT202200013T1/it unknown
- 2018-07-06 MY MYPI2019007689A patent/MY200797A/en unknown
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 MX MX2020000402A patent/MX394089B/es unknown
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| CL2020000056A1 (es) | Nuevos derivados de xantina sustituidos. | |
| AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
| CR20180320A (es) | Compuestos inhibidores de la quinasa de union a tank | |
| MX2017012380A (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CL2016001131A1 (es) | Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones. | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
| CO2017001601A2 (es) | Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio | |
| CO2018008445A2 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca | |
| CL2018003417A1 (es) | Nuevos compuestos. | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| MX389026B (es) | Una composicion farmaceutica y el uso de la misma. | |
| JOP20200126B1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| PL3595693T3 (pl) | Formulacje i dawkowanie kannabinoidów | |
| MX2021007019A (es) | Derivados de xantina sustituida. | |
| CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX368735B (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. |